Literature DB >> 28084542

Need for improvements in reported cost effectiveness of adalimumab in rheumatoid arthritis.

S Weber1, G Pongratz1, M Schneider1, R Brinks2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28084542     DOI： 10.1007/s00393-016-0255-3

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN： 0340-1855            Impact factor:   1.372


× No keyword cloud information.
  3 in total

1.  Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies.

Authors:  Milton C Weinstein; Bernie O'Brien; John Hornberger; Joseph Jackson; Magnus Johannesson; Chris McCabe; Bryan R Luce
Journal:  Value Health       Date:  2003 Jan-Feb       Impact factor: 5.725

Review 2.  Review of guidelines for good practice in decision-analytic modelling in health technology assessment.

Authors:  Z Philips; L Ginnelly; M Sculpher; K Claxton; S Golder; R Riemsma; N Woolacoot; J Glanville
Journal:  Health Technol Assess       Date:  2004-09       Impact factor: 4.014

3.  EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor inhibitors: a prospective cohort study from southern Sweden.

Authors:  Anders Gülfe; Johan K Wallman; Lars Erik Kristensen
Journal:  Arthritis Res Ther       Date:  2016-02-19       Impact factor: 5.156
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.